ArticleThe Journal of general virology2025
Translocating shRNA: a novel approach to RNA interference with Newcastle disease virus as viral vector.
Article in The Journal of general virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Potential Use of Matrix Metalloproteinases in Alzheimer's Disease Therapy.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference is crucial in post-transcriptional gene silencing. Short hairpin RNA (shRNA) is particularly effective because it forms fully complementary matches with target mRNA, leading to its degradation. However, shRNA processing relies on nuclear microprocessors like Drosha, posing a challenge for RNA viral vectors that replicate exclusively in the cytoplasm. Although there have been reports of Drosha translocating to the cytoplasm upon viral infection, many RNA viruses, including Newcastle disease virus (NDV), remain inadequately studied in this context and, in some cases, fail to induce Drosha translocation for shRNA processing. In this study, we developed a novel approach to translocate an shRNA, expressed by NDV as an RNA viral vector, into the nucleus for Drosha processing. As a proof of concept, a recombinant NDV expressing the shRNA (rAF-shmcherry) with an AU-rich region at its 3' end in the expression cassette was constructed. This shRNA targets a constitutively expressed mCherry gene in a colorectal cancer cell line, SW620-mC. We confirmed the presence of the AU-rich shRNA in the nuclei of the rAF-shmcherry-infected SW620-mC using reverse transcription PCR (RT-PCR). The gene-silencing effect of the shRNA was then evaluated at mRNA and protein levels, showing ~90% downregulation of the mCherry transgene at 24 h post-infection and 70% downregulation of mCherry protein in SW620-mC at 48 h post-infection. This study marks the first exploration of NDV as an shRNA viral vector, presenting a promising approach for shRNA translocation that could be applicable to various RNA viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.